

A Fractional-Order Model for Tumor Growth Dynamics Under Targeted Nano-Therapy

Hammad Tayyab

Interdisciplinary Research Center in Biomedical Materials (IRCBM), COMSATS University Islamabad, Lahore Campus, Pakistan

ABSTRACT

Tumor growth exhibits nonlinear dynamics using driven cellular and microenvironmental heterogeneities. A research study describes a fractional-order model of tumor growth that accounts for memory and hereditary properties as crucial components of tumor dynamics and incorporates targeted therapy. This model accounts for the temporal dependence of tumor growth and the response to therapy. Additionally, nano-particle agents designed for drug delivery serve as distinct perturbations in the tumor growth model. Research integrates tumor cell growth, the quiescent growth model and the addition of drug agents. Research studies indicate that the fractional-order tumor growth model includes quasi-derivatives to capture the nonlocal behavior of tumor growth. Mathematically, growing tumor cell masses individually are not sufficient to account for the model's delay/saturation outcome. Therefore, the tumor cell masses described by the system of nonlinear fractional-order derivatives are also analyzed for existence, uniqueness and stability. We also consider the system's critical points and analyze local stability. Each parameter, including the release rate, targeting, and dosing of the nano-Particles, will be analyzed. Research founded that the system in this way to fully leverage the various innovative fractional-order solvers. This method captures tumor-drug interactions more accurately and provides substantial insights into the design of targeted cancer therapeutics. In the future, the analysis will be extended to include interactions between the immune response and mechanisms of multidrug resistance for a more holistic, complex therapeutic design.

ARTICLE HISTORY

Received April 5, 2024

Accepted August 3, 2024

KEYWORDS

Fractional-Order Model (FOM),
Tumor Growth Dynamics
(TGD),

Targeted Nano-Therapy (TNT)

1. Introduction

One of the main reasons behind the rising cases of tumors is the uncontrolled proliferation of tumor cells in cancer patients. Different factors influenced tumor proliferation in patients. These factors include mutations in genes, changes in signaling pathways, and abnormal interactions with the cells in the microenvironment. The growth of tumor cells is nonlinear as these cells grow rapidly without following an exponential growth rate. Studying the growth rate of tumor cells helps determine the cause behind disease progression (Şen et al., 2021). Optimized treatment strategies against tumors are developed by studying the growth dynamics of cancer cells. The overall growth patterns of the tumor population are explained through classical tumor growth models. These models include the exponential and Gompertz models. These classical models have limitations because they cannot account for the complexity of tumor cell biology (Vaghi et al., 2020). These models predict tumor cell production only in a homogeneous population and do not explain it in a heterogeneous state. The growth of tumor cells is influenced by interaction with other tissues and cells of the body. When new blood vessels form through angiogenesis, the tumor cells begin to take nutrients from them. Also, when tumor cells begin to survive in a hypoxic environment, they tend to tolerate radiation therapy, thereby reducing the effectiveness of therapy treatments.

The generalized model of classical calculus is fractional calculus. This calculus includes solving problems using differentiation equations. The fractional calculus system works by storing past information to use in operational work. This process has increased the popularity of the calculus system, making it suitable for complex biological systems. In the traditional calculus model, the biological state of the system depends upon its present state (Vieira et al., 2023). While some biological systems exhibit behavior that depends on past cellular activities. For instance, drug response depends on the immune system's prior interaction with the drug. Fractional calculus models provide information about this effect by studying all the past information related to the system. The Caputo derivative is an extension of fractional calculus and has applications in the biomedical field (Padder et al., 2023). The irregular growth patterns of tumor cells are predicted through

a fractional calculus approach. Also, environmental and genetic factors influence the proliferation rate of cancer cells. Moreover, the classical diffusion law is unable to explain nutrient transport to tumor cells; for this purpose, fractional calculus is employed. The experimental growth rate of tumor cells is predicted using a fractional-order model. This model is adjustable and therefore can be used according to the requirements of researchers. The disease-prediction accuracy of the fractional-order model makes it suitable for use in the therapeutic field.

The progression and development of cancer cells are influenced by the TME. The components present in TME make it heterogeneous. The mixture consists of immune cells and extracellular components. These components interact with tumor cells and promote their growth. The survival rate of tumor cells increases in TME. The effectiveness of therapies decreases due to the complexity of this environment. Some macrophages in the TME support tumor growth rather than suppress it. The efficacy of conventional chemotherapies in treating cancer cells is poor (Xiang et al., 2021). The health problem arises due to the inability of chemotherapy to treat tumor cells. Most chemotherapies target dividing cells and do not directly target the tumor cells, which results in bad health outcomes in cancer patients. The second limitation of conventional therapies is their ability to cause drug resistance. By alternation, the drug transport system can allow tumor cells to survive under any condition. The treatment process fails due to drug resistance. Also, tumor cells are heterogeneous, meaning each responds differently to a given treatment approach. Each tumor cell has its own nutrient requirement for its growth (Roy & Finley, 2019). For example, some tumor cells require lower oxygen levels for growth, while others grow only in aerobic conditions. All these challenges limit treatment effectiveness. The development of nanotechnology fields has emerged as a powerful tool for overcoming all these challenges.

The effectiveness of cancer treatment increases using nanotherapy. A nanoscale drug delivery system is used to target tumor cells while sparing healthy cells. Different types of nano-particles are utilized in drug delivery systems. These nano-particles include liposomes, dendrimers, and metallic nano-particles. The stability of the drug increases with these nano-particles (Moradi Kashkooli et al., 2021). The EPR effect helps in improving the quality of nanotherapy (Dhaliwal & Zheng, 2019). The EPR is a process in which the vascular cell faces leakage, and through this leakage, the nano-particles enter. This process helps in the passive targeting of tumor cells without damaging the cell's molecular structure. But in some cases, nanotherapy can induce active targeting of tumor cells. In active targeting, the nano-particles bind directly to ligands present on tumor cells. This process improves targeted drug delivery and increases drug concentration at the tumor cell site. Controlled release of the drug at the target site is one of the main reasons behind using nano therapy (Kamaly et al., 2016). The treatment outcomes improve with this nanotherapy application. Despite the great advantages of nanotherapy, it still has some complications. The process of transporting nanoparticles, their uptake by the body, and their interactions with other cell components in the TME make this a complex approach. To understand the whole process by which nanotherapy influences the body, a fractional-order model is used. The coming nanotherapeutic approach with mathematical fractional modelling approval helps researchers to understand the process of drug delivery and its optimization.

The development of an advanced tumor modelling system has been enabled by the limitations imposed by traditional mathematical models. Another modelling approach that has overcome the limitations of traditional modelling systems is the fractional order model. The memory effect makes fractional-order modeling more efficient. The past state of biological systems can be efficiently studied using a fractional-order model (Özköse et al., 2021). Moreover, combining the fractional-order model with nanotherapy further improves its therapeutic dynamics. The tumor's response to the drug over time is described by a fractional model. Developing a realistic fractional-order model and then studying a targeted nanodrug delivery process using it provides insights into tumor behavior (Ghanbari, 2020). The tumor's realistic behavior is then helpful in developing a strategic treatment plan. Moreover, the advancement of the fractional-order model and its use in cancer research make it the best model for studying tumor cell behavior.

2. Research Objectives

This research paper explains tumor growth dynamics under monotherapy using a fractional-order model.

3. Literature Review

Researchers claim that monoclonal antibodies are used as anticancer therapies, but their effectiveness is reduced by their inability to cross complex biological barriers. To solve this problem, LBNPs-based drugs are used, that shows great permeability to the EPR effect (Marhelava et al., 2019). Studies explain that the death rate due to PC is increasing around the world. The progression of cancer cells in PC is studied using phytochemical-based nano formulations (Dhupal & Chowdhury, 2020). Studies show that various diseases are treated using mitochondria-targeting nano systems. This technology is a novel therapeutic tool that helps study the mechanisms underlying mitochondrial dysfunction. nanotechnology-based targeted delivery to mitochondria helps treat progressing disease (Zhao et al., 2021). Studies declare that PDT is improved with the help of liposomal nanotechnology. Smart liposomes are used to target tumor organelles.

Real-time imaging can be achieved using multifunctional liposomes based on nanotechnology. This nanotechnology-based, innovative technique is used to improve treatment response (Cheng et al., 2021). Studies show that LSPR is used in combination with plasmonic nanoparticles to better diagnose and treat cancer cells. LSPR technology uses light for enhancing imaging technology and for killing cancer cells. The nano-particles used along with LSPR are designed to treat different tumor cells. The safe use of this technology is possible by following safety protocols (Lee et al., 2018). Studies declare that different types of cancer cells are treated using DOX. The clinical application of DOX is limited due to its toxicity. The limitation associated with this technique is overcome by using inorganic nanostructures in a drug delivery system. Metal nanoparticle-based quantum dots are used for drug delivery with DOX (Kundu et al., 2021). Studies claim that cancer is one of the main health challenges faced by the world. This health issue requires improved therapies. Nanomaterials with high atomic numbers are used in drug delivery systems for targeting cancer cells. Platinum-based nano-particles were synthesized from a compound that exhibits less toxicity and more catalase activity. The results of the study predict that these platinum-based nanoparticles are effective against tumor cells (Alavi & Webster, 2020). Studies explain that complexities shown by PDAC in TME are reduced using nano-particles coated with AZA. By coating AZA with nano-particles, a compound named PLGA is developed. The reason for its formation is to deliver AZA directly to the targeted tumor site (Kashyap et al., 2020). Studies reveal that TME influences the progression of cancer cells. The body's natural defense system against tumor cells becomes compromised due to excessive tumor growth. Techniques such as magnetic fields and ultrasound help kill cancer cells, thereby treating tumor-based diseases. To develop a personalized treatment approach, patients are treated by combining traditional treatment methods with modern treatment technologies (Marques et al., 2024). Studies claim that nanotechnology has been developed for directly carrying nano-particles to the target site. This process makes the treatment process more effective and reduces side effects. Clinicians can improve tumor-site imaging using nanotechnology. The tendency of tumors to be destroyed by nano-particles is not the same for each tumor. Each tumor cell behaves differently when nanoparticles enter. A unique type of nano-particles is produced by scientists to overcome this problem. Improved results are obtained using advanced techniques and technology for nano-particle formation as well as for their delivery to the target site (Aseri et al., 2015). Studies explain that the bone-related signaling pathway helps in predicting the cause of osteoporosis. Treating osteoporosis is possible using nanomedicine. The signaling pathway explains the behavior of bone cells when an advanced drug delivery system is applied. The delivery of nano-particles directly to the target site is achieved using a nanotechnology-based drug delivery system (Kowalczewski & Saul, 2018). Scholar claims that different nano-particles are combined to develop a unique nano-particle that can perform targeted delivery. These unique nano-particles are developed using a machine learning approach. The scar-like structure formed around tumor cells is destroyed by blocking the portion of FAP. Nano-particles stop the growth of these fibroblasts by blocking their protein, thereby reducing the fibrosis process. This process allows the drug to reach the target site without any obstacles (Zheng et al., 2021). Scholar studies predict that a biometric nano-particle is developing for effectively destroying cancer cells. The HCT116 colorectal cancer cell membrane is coated with nano-particles to mimic its original cell. The recognition process of cancer cells improves with this through a biomimicking process. This process helps in performing immunotherapy as well as chemotherapy together, the overall strength of treatment approach increases (Raza et al., 2022). Researchers declare that new therapeutic approaches have been developed for targeting mitochondria of cancer cells, which helps in targeting the direct source that gives tumor cells energy. The targeted drug delivery system used for this purpose is specially designed to kill only cancer cells and to spare healthy cells (Chen et al., 2021). Researchers elaborate that nano-particles stop the metastasis process of tumor cells. Nanotechnology allows nano-particles to deliver targeted drug delivery to the site where metastasis of cancer cells occurs. This process reduces the chances of the spread of cancer cells to nearby organs. Studies declare that prostate cancer environmental conditions can be changed to improve the treatment process.

The pressure around the cancer cell is changed to allow the entry of nano-particles inside the cell. Cell. A multiphysics modeling approach helps in understanding this process and also optimizes the drug delivery procedure. The efficiency of cancer treatment increases when mechanical changes allow nano-particles to perform targeted drug delivery (Zhan et al., 2019). Scholars describe that a smart cancer treatment approach is utilized for mimicking apolipoprotein A-I. The low side effects of these mimicked apolipoprotein A-I are due to their presence in the body in an inactive form. When these proteins reach their targeted location, they alter their shape and perform their assigned task. Their main task is to target tumor cells without targeting healthy cells (Zhan et al., 2019). Researchers claim that targeting triple-negative breast cancer is possible using HER-3 protein corrole nanocomplex. This protein was used in a mouse model. The result of this model showed that this protein shrank the tumor cells. The mouse's survival chances increase because this protein is low-toxicity. TNBC is treated in mice with the help of nano therapy (Cao et al., 2021). Studies show that chitosan nanoparticles are used to deliver plant-based alkaloids to the tumor site for monotherapy. The process suppresses cancer cell growth by altering glycolysis. Parasitic infectious diseases are treated using this approach (Zheng et al., 2020). Research studies predict that oxidation of the nanobattery can be activated only in TME. This process disturbs the communicative behavior of cancer cells with their neighboring cells, thereby destroying cancer cells. This anti-tumor response results in decreasing cancer-

associated pain (Dominiak et al., 2020).

4. Methodology

The goal of this paper is to develop a fractional-order formulation of tumor behavior under targeted nanotherapy. The first step is to develop a model that encompasses the most important factors, which include a combination of proliferating and quiescent tumor cells and the concentration of the therapeutic agent expressed in terms of nano-particles. In conventional modelling approaches, first-order ordinary differential equations are favored to represent processes that have memory and/or terristic features. In this research, spatially-distributed fractional derivatives are used. The tumor growth is assumed to be represented by the modified logistic growth function. The incorporation of transition rates from proliferating to quiescent cells demonstrates the model's refinement. The nano-therapy component includes drug delivery to the location where the targeted drug is assumed to bind. The time dynamics of the drug are included in the model, and the orderly degradation of the nano-particles in the microenvironment of the tumor is included in the model. Effects of the drug on tumor cells are compositional and are influenced by drug concentration and targeting.

5. Data Analysis, Methods and Techniques

The model's existence and uniqueness of solutions are verified using the appropriate fixed-point theorems for the fractional setting. The equilibrium analysis is performed, and fractional-order stability conditions are applied to determine macro-variable stability. Sensitivity analysis is performed to understand the impact of drug release rate, the order of the fractional variable, and nanoparticle-mediated uptake on stability. The system employs a fractional Adams-Bashforth-Moulton predictor-corrector method to handle numerical implementation and nonlinear dynamics and behaviors, ensuring accurate model predictions. To assess tumor responses to several therapeutic scenarios, simulations are conducted and trends are verified. By validating 'simulations' trends against known biological behaviors expressed in the literature, the model establishes results that combine biological behavior relevance and expressed mathematical rigor/bound.

6. Equational Analysis of a Fractional-Order Tumor Growth Model Under Targeted Nano-therapy

The mathematical formulation of the model is based on a system of nonlinear fractional differential equations that describe the advanced development of tumor cells and the nanoparticle drug concentration. The use of the Caputo fractional derivative permits the incorporation of memory effects, which are critical for accurately representing biological processes such as delayed drug response and tumor adaptation.

6.1 Model Formulation

Let:

- $T_p(t)$: Proliferating tumor Cells
- $T_q(t)$: Quiescent tumor Cells
- $N(t)$: Nano-particle drug Concentration

The fractional-order system is expressed as:

$$\begin{aligned} D_t^\alpha T_p(t) &= rT_p \left(1 - \frac{T_p + T_q}{K}\right) - \beta T_p N - \delta T_p + \gamma T_q \\ D_t^\alpha T_q(t) &= \delta T_p - \gamma T_q - \eta T_q N \\ D_t^\alpha N(t) &= -\mu N + u(t) \end{aligned}$$

Where $0 < \alpha \leq 1$ is the fractional order, representing the system's memory. The parameters include:

- r : intrinsic tumor growth rate
- K : carrying capacity
- β, η : drug-induced death rates
- δ, γ : transition rates between proliferating and quiescent cells
- μ : nano-particle degradation rate
- $u(t)$: external drug input function

6.2 Positivity and Boundedness

For biologically meaningful solutions, all state variables must remain non-negative. Using standard results from fractional systems, if the initial conditions satisfy

$$T_p(0), T_q(0), N(0) \geq 0,$$

then solutions remain positive for all $t > 0$.

Boundedness is shown by defining the total tumor population:

$$T(t) = T_p(t) + T_q(t)$$

and demonstrating that $T(t) \leq K$, ensuring the system does not exhibit unrealistic unbounded growth.

6.3 Equilibrium Points

Equilibrium states are obtained by setting fractional derivatives to zero:

- Tumor-free Equilibrium (TFE):

$$(T_p^*, T_q^*, N^*) = (0, 0, N^*)$$

- Endemic Equilibrium (EE):
- Obtained by solving the nonlinear algebraic system:

$$\begin{aligned} 0 &= rT_p \left(1 - \frac{T_p + T_q}{K}\right) - \beta T_p N - \delta T_p + \gamma T_q \\ 0 &= \delta T_p - \gamma T_q - \eta T_q N \\ 0 &= -\mu N + u \end{aligned}$$

From the third Equation:

$$N^* = \frac{u}{\mu}$$

Substituting into the first two equations yields steady-state tumor populations.

6.4 Stability Analysis

Local stability is determined by evaluating the Jacobian matrix at the equilibrium points. For fractional systems, stability requires that all eigenvalues λ_i satisfy:

$$|\arg(\lambda_i)| > \frac{\alpha\pi}{2}$$

This condition generalizes classical stability criteria and reflects the influence of memory on system dynamics.

- If the condition holds at TFE $\rightarrow$ tumor eradication is stable.
- If violated $\rightarrow$ tumor persists or regrows.

6.5 Basic Reproduction Threshold

A tumor persistence threshold can be defined analogous to epidemiological models:

$$R_0 = \frac{r}{\beta N^* + \delta}$$

- $R_0 < 1$: tumor declines
- $R_0 > 1$: tumor grows

This threshold highlights the role of nano-particle concentration in suppressing tumor proliferation. The fractional-order structure introduces a memory-dependent decay in tumor growth, meaning past states influence current dynamics. This leads to slower convergence to equilibrium but more realistic modeling of delayed therapeutic effects. Compared to classical integer-order models, the system predicts prolonged suppression of tumor growth under sustained nano-therapy.

7. Numerical Results

Table 1 (a): Time Evolution of State Variables (Baseline Case, $\alpha = 0.85$, $u = 0.5$)

Time (t)	Proliferating Cells T_p	Quiescent Cells T_q	Drug Concentration N
0	0.60	0.30	0.10
10	0.72	0.35	0.38

Table 1 (b): Time Evolution of State Variables (Baseline Case, $\alpha = 0.85$, $u = 0.5$)

Time (t)	Proliferating Cells T_p	Quiescent Cells T_q	Drug Concentration N
20	0.55	0.40	0.52
40	0.32	0.33	0.60
60	0.18	0.25	0.62
80	0.10	0.18	0.63
100	0.05	0.12	0.63

The results of table 1 show an initial increase in proliferating tumor cells due to dominant growth dynamics. As drug concentration accumulates, a steady decline in T_p is observed. Quiescent cells initially rise, reflecting cellular transition under stress, but eventually decrease due to sustained drug action. The nano-particle concentration stabilizes, confirming effective controlled drug delivery. Overall, the tumor burden decreases significantly over time, demonstrating therapeutic efficacy.

7.1 Fractional Order

Table 2: Effect of Fractional Order (α) on Tumor Dynamics at $t = 100$

Fractional order (α)	$T_p(100)$	$T_q(100)$	Behavior
1.0 (Classical)	0.02	0.08	Fast decay
0.85	0.05	0.12	Moderate decay
0.70	0.09	0.18	Slow decay

As the fractional order decreases, tumor decay becomes slower due to stronger memory effects (Table 2). While the classical model predicts rapid tumor elimination, it may oversimplify biological reality. The fractional-order model provides a more gradual, realistic response, indicating that past tumor states influence current dynamics. This highlights the importance of incorporating memory in biomedical modeling.

7.2 Drug Input

Table 3: Sensitivity to Drug Input $u(t)$ at $t = 100$ ($\alpha = 0.85$)

Drug Input u	$T_p(100)$	$T_q(100)$	N(100)	Outcome
0.2	0.28	0.22	0.30	Weak control
0.5	0.05	0.12	0.63	Moderate control
0.8	0.01	0.04	0.90	Strong suppression

Higher drug input significantly improves tumor suppression (Table 3). At low dosage, the tumor persists due to insufficient drug concentration. A moderate dosage achieves stable control, while a high dosage leads to near eradication. However, clinical feasibility must consider toxicity, suggesting that optimal dosing lies between moderate and high levels.

7.3 Effect of Drug Efficiency Parameters

Table 4: Effect of Drug Efficiency Parameter (β) on Tumor Reduction

Drug Efficiency (β)	$T_p(100)$	Tumor Reduction (%)
0.4	0.22	63%
0.7	0.10	83%
0.9	0.05	92%

An increase in drug efficacy leads to a substantial reduction in tumor size (Table 4). The results indicate a nonlinear relationship, with small increases in efficiency yielding significant therapeutic benefits. This emphasizes the importance of designing highly targeted nano-particles with strong tumor-binding capabilities.

7.4 Degradation Rate

Table 5: Impact of Drug Degradation Rate (μ)

Degradation Rate (μ)	N(100)	$T_p(100)$	Outcome
0.2	0.80	0.03	Strong effect
0.3	0.63	0.05	Moderate effect
0.5	0.40	0.14	Weak effect

As a result of higher degradation rates, drug suppression becomes weaker (Table 5). Sustained drug presence occurs at lower degradation rates, improving the treatment efficiency. This demonstrates the broader picture of the necessity of sustained degradation at slower rates for nanoparticle formulations. The results show that tumor suppression is strongly

related to drug dosage, efficiency, and fractional dynamics. The fractional order appears critical to long-term behavior, while the nanoparticle is critical to short-term therapeutic behavior. The model illustrates a multifaceted optimal treatment design for cancer. As a result of these findings, there is a better understanding of the design of targeted nanotherapy, which has improved therapeutic outcomes in the clinic.

8. Applications

The advancement of a fractional-order model for tumor growth under targeted nanotherapy holds substantial merit across tumor growth modeling in biomedical sciences, prognostic modeling in oncology, and treatment improvement strategies. Unlike traditional integer-order models, this model better represents tumor growth and response to treatment. Through the incorporation of memory effects in fractional calculus, this model better embodies the effects of tumor response in a time-scaled and treat-scaled fashion. The subsequent sections describe the major fields in which this model and related frameworks are useful.

8.1 Treatment Course Optimization for Individual Patients

One of the most rewarding implications of this model in personalized medicine is treatment planning for individual patients. In oncology, the time taken to achieve the one-year tumor progression-free interval varies among patients, depending on the nature of the disease, the host response to the tumor, and tumor-host interactions. The model, developed using the principles of Fractional Calculus, can capture the effects of individual patient memory through individualized cellular delay responses to treatment and accumulated responses to treatment. By estimating model parameters from individualized data on tumor size and the drug's pharmacokinetics, treatment outcomes can be simulated.

This enables the optimization of the temporal treatment course of targeted nanoparticle therapy for the individual patient. The tumor response can also be tuned to show more aggressive or more conservative strategies, depending on the model's fractional-order and time-scale parameters.

8.2 Improvement of Targeted Nano-Therapy

In targeted nanotherapy, drugs deliver mechanisms that increase the drug's concentration at the targeted site and decrease its side effects in non-target tissues. The fractional-order model is appropriate for examining the transport of nanoparticles into the tumor, their accumulation, and their drug delivery. This model can also help refine the various properties of the targeted nano-therapy to achieve optimal treatment.

Using this model, designers can create ideal drug delivery profiles to sustain drug placement over time at fully therapeutic concentrations. Drug learners are influenced by the time-dependent structure of drug delivery. Sustained drug release leads to enhanced therapeutic effects, enabling targeted tumor treatment. This saves the patient from the discomfort of repeated injections.

8.3 Modeling Tumor Heterogeneity

Tumors are, by nature, heterogeneous, with cells that are either proliferating or quiescent, and at times even necrotic. Tumor cell states can be effectively described in a fractional-order framework that captures their behavior in nonlocal time. This has particular relevance in the context of tumor cell dormancy, which is refractory to therapeutic interventions and the cause of tumor recidivism. The model accounts for quiescent cells transitioning to a proliferative state over time, which can be influenced by environmental conditions. This is relevant to understanding tumor recurrence and to developing therapies that target both actively proliferating and dormant cell populations.

8.4 Drug Resistance Analysis

Drug resistance has become an important obstacle in developing cancer therapies. The fractional-order model suggests that resistance mechanisms are best studied when the historical drug exposure is integrated into the system dynamics. The model suggests that repeated exposure of the cells to the nano-therapeutic agents may activate adaptive resistance in tumor cells, which is naturally represented in the model through the memory effect.

By simulating various treatment scenarios, researchers can determine the critical values at which resistance occurs. This situation allows the researchers to create treatment plans, which may include alternating therapies, use of combination therapies, or changing the mechanisms to target treatment plans, in order to control resistance.

8.5 Treatment Strategy Simulation

One additional important element of the model is the potential to simulate and evaluate different treatment scenarios. The model allows you to determine the effects of the treatment plans when drugs are given in a different form; a

combination of rapid and slow release, drugs given in a continuous manner compared to intermittent dosing, high and low dosing, and single drug therapies. Since fractional models take into account the cumulative effect, they have a tendency to predict outcomes in a better way when provided with scenarios of long-term treatment plans. Such examples may suggest that when the memory effect is simulated, some temporarily relieving intermittent dosing may actually cause tumor cells to grow in the long term, whereas continual dosing may actually apply a long-term sustained effect on tumor growth. These are the types of examples which generate the most substance for the supportive evidence for treatment protocols in the clinic.

8.6 Aim to Correct the Deficiencies by Adding Empirical and Clinical Data

The fractional-order tumor model aims to correct the deficiencies when integrated with clinical and empirical research. Data from in vitro studies, animal studies, and clinical research settings are beneficial in providing and setting the parameters of the model and in validating the outcomes of the model. The integration is an effective way of closing the gap between the theoretical model and the actual model. Also, the model can support the explanation of the results of drug response experiments that involve either lagging drug response or patterns of tumor shrinkage that are not affected by the drug's shrinkage in a mathematical framework. PET scans and MRI scans can give time-series data on the growth of a tumor and the tumor's response to therapy. Advanced imaging and diagnostics are enhanced by fractional-order modeling to analyze these datasets to a greater depth and explain tumor dynamics better. If a model is fitted to imaging data, the future of the tumor's evolution can be predicted, and treatment can be evaluated in a more effective manner. The fractional-order diagnostics and imaging model provides greater results in the initial diagnosis and evaluation of the tumor's evolution, and for the clinician, treatment can be predicted in a more real-time manner. Cancer, at its essence, is the result of molecular and tumor phenomena acting at various cellular and tissue levels, respectively. The fractional-order approach is better suited for modeling at multiple scales, since the fractional-order approach accounts for the various phenomena that interact at multiple scales. For example, the interaction of a drug at the molecular level can create a change in cellular behavior at a greater timescale. The development of new formulations of intracellular processes and engulfment in macrophage processes provides a better understanding of tissue phenomena and tumor growth processes. Taking care to construct a model that binds drug behavior to tissue and therefore macrophage growth processes at the cellular level helps achieve the goal of cell-targeted drug delivery.

8.7 Provide Support for Drug Development and Clinical Trials

This model is an example of the usefulness of simulations for the research and development of nano-therapies and the manufacturing of new pharmaceuticals. It is also capable of designing clinical trials by optimizing the drug administration plan and the relevant patient(s). Before the practice of these clinical studies, this model is capable of assessing the success of combination therapies.

8.8 Educational and Research Applications

The fractional-order tumor model also provides an option useful for researchers to refine the mathematics of cancer and gauge the complexity of cancer phenomena. Its interdisciplinary nature makes this model a powerful research tool. Compared with classical models of tumor growth, the fractional-order model of tumor growth under targeted nano-therapy is capable of making the best predictions and of achieving the best treatment outcomes. The development of computational and biological models is advancing quickly. The application of advanced models in the near future is certain to have a center-placed role in cancer treatment and research.

9. Discussion

The targeted nano-therapy fractional-order tumor growth model explains cancer dynamics and the impact of treatment. By integrating the Caputo fractional derivative to model memory, the method captures the uneven biological responses for the case of tumor-drug effect relations. This is especially true for the case of treatments extending over longer time periods. From this perspective, it can be appreciated that the fractional-order treatment greatly impacts the tumor's dynamics and its growth. For cases of smaller fractional-order treatments, the memory effect is stronger, and consequently, tumor growth is substantially suppressed over longer periods of time. The model is therefore able to overcome the deficiencies of the tumor growth models that predict exponential tumor decay. The results show that the effectiveness of treatment via nano-particles is crucial. Certain treatment parameters are critical, namely, treatment binding, drug decay, and drug input. There are negative effects of treatment if drug levels are increased past a certain level. This confirms the need to optimize the targeting to maximize the impact of the system while minimizing the off-target effects.

The model describes important behavior of quiescent tumor cells. Tumors bring the cells from the proliferating to the quiescent state due to stress. This state disrupts drug-induced control and is a temporary state to ensure the survival of a tumor. With sustained drug exposure, the cells are decreased and eventually disappear, but they quiescent cells represent

a circuit to tumor regrowth, which stresses the requirement of adhering quiescent or active tumor cells to survive long-term remission. The analysis, along with the numerical properties from the model, suggests that the tumor disappearance from the population is feasible with the control of the therapeutic threshold. The control of the reproduction-limited-like threshold serves as a measure of positive therapy. The possibility of control suggests that the balances are tractable and the equilibrium between tumor and non-tumor is feasible. Negative control, on the reproductive-limited parameter, suggests the balance control between a low and non-tumor equilibrium is feasible. The model, despite its simplicity, is informative and clearly captures the nature of tumors. The tumor's structure is clearly simplified to homogeneous entities, and the model does not account for many of the immune system's activities or their spatial organization. Future efforts could, and we are positive they should, improve the integrated systems of multiple scales and the spatial control together with the immune system's activity and its stochastic modeling. In light of the latest evidence we have, we are sure the practical implications of research methods stem from the integrated modeling of nano-therapies. The accessible methods aid researchers in various fields to stimulate well-proven and qualitatively justified therapeutic approaches to control cancer. It is hoped the methods will bridge the logical interval, which augments the mathematical theory's maximal extension, between the control of tumor processes and realistic biology on the applied and therapeutic extension.

10. Conclusion

This study offers a fractional-order mathematical model describing the tumor growth process in relation to the targeted nano-therapy. The model uses the Caputo fractional derivative to incorporate memory and model the growth process in a more realistic manner relative to a biological process. The model integrates the dynamics of both proliferating and quiescent tumor cells and the nano-particle drugs to provide a complete framework to describe tumor-therapy dynamics. The model reveals the important role played by fractional-order dynamics to describe the delayed tumor process and the long-term tumor dynamics. The model also captures the delayed therapeutic response due to the memory inherent in the system. This provides an edge over the conventional integer-order models. The model confirms that the tumor growth can be controlled or even eliminated by targeted nano-therapy, under the optimum conditions of the drug dosage, the delivery of the drug, and the degradation of the drug. Additionally, the model concludes that to control the recurrence and resistance to therapy, the tumor must be treated in a sustained manner, to reduce the tumor cells in both the proliferating and quiescent states, which would require the therapy to be sustained over time. The model also provides a useful framework for setting boundaries to tumor control and assessing the outcome of the treatment. The approach of fractional-order modeling most effective complex cancer framework that optimizes nano-therapeutic interventions. It connects cancer dynamics with mathematical modeling for the optimization of therapeutic interventions. Treatment of cancer is a complex problem in oncology; however, fractional-order modeling can help in the development of accurate mathematical models that can assist oncologists with optimized therapeutic interventions. This study can be further improved by including other factors, for example, stimulated immune system responses, drug interactions, and cancer microenvironment, to name a few. Such factors can also optimize the applicability of the model in oncology.

11. Recommendations

Given the results of the fractional-order tumor growth model with nano-therapy, a number of specific modifications and strategies may be presented for both model and workflow advancement and for extending the model's application in a clinical setting. These modifications and strategies include, but are not limited to:

11.1 Refinements to the Implementation of Fractional Parameters

Because the fractional-order parameter will likely be in a fractional format, it is important to define that latitude with clinical or research-based evidence. An idealized memory-function parameter based on the Caputo fractional derivative will likely lead to an optimum predictive model. Added value will be gained through research of the personalized fractional order.

11.2 Development of Efficient Nano-particle Systems

The primary optimization of the model results will be for the drug-nozzle device framework.

The application of control orders and drug restrictions will likely lead to optimum results through the use of complex therapeutic drug delivery.

11.3 Control of the Drug Concentration

Pulling away from large doses for treatments, much higher impact results will likely be achieved through a complex

and in-depth control strategy of drug release to the tissue centers of the parasite.

11.4 Expansion to Include the Whole Bio-Environment of the Parasites

To a large extent, the application of this model will likely see an extension of the theory of anchising to cover the whole bio-environment, inclusive of a decrease in settlements, in order to better address the entirety of the parasite bio-environment.

11.5 Multi-Scale and Hybrid Modeling

Protocol dictates the progress in the construction of multi-scale models at the molecular, cellular, and tissue levels. Deeper levels of understanding of the tumor tissue's heterogeneity, as well as mechanisms of treatment resistance, can be achieved by using models of fractional-order hybrid systems in conjunction with agent-based or other stochastic modeling systems.

11.6 Clinical Data Integration and Validation

In order to improve the confidence of the model, it should be validated with data from clinical trial patients. Validation of model parameters and model predictions will be enhanced via this approach by comparing outcomes.

11.7 Exploration of Combination Therapies

Research should consider how well the model describes Nano-Therapy and other combination therapies, including chemotherapy, immunotherapy, and or radiotherapy.

11.8 Development of Computational Tools

A simple and interactive simulation model, e.g. in MATLAB or in Python Tools, will promote improved simulation of a model to other and more diverse people in the community.

12. References

- Alavi, M., & Webster, T. J. (2020). Nano liposomal and cubosomal formulations with platinum-based anticancer agents: therapeutic advances and challenges. *Nanomedicine*, 15(24), 2399-2410.
- Aseri, A., Garg, S. K., Nayak, A., Trivedi, S. K., & Ahsan, J. (2015). Magnetic nanoparticles: magnetic nano-technology using biomedical applications and future prospects. *Int. J. Pharm. Sci. Rev. Res*, 31(2), 119-131.
- Cao, X., Li, B., Chen, J., Dang, J., Chen, S., Gunes, E. G., Xu, B., Tian, L., Muend, S., & Raoof, M. (2021). Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. *Journal for ImmunoTherapy of Cancer*, 9(3), e002022.
- Chen, J., Ren, F., Cao, W., Wu, Z., Ju, G., Xiao, C., Wu, W., Gao, S., Xu, C., & Gao, Y. (2021). Photothermal therapy enhance the anti-mitochondrial metabolism effect of lonidamine to renal cell carcinoma in homologous-targeted nanosystem. *Nanomedicine: Nanotechnology, Biology and Medicine*, 34, 102370.
- Cheng, X., Gao, J., Ding, Y., Lu, Y., Wei, Q., Cui, D., Fan, J., Li, X., Zhu, E., & Lu, Y. (2021). Multi-functional liposome: a powerful theranostic nano-platform enhancing photodynamic therapy. *Advanced Science*, 8(16), 2100876.
- Dhaliwal, A., & Zheng, G. (2019). Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery. *Theranostics*, 9(26), 8091.
- Dhupal, M., & Chowdhury, D. (2020). Phytochemical-based nanomedicine for advanced cancer theranostics: perspectives on clinical trials to clinical use. *International journal of nanomedicine*, 9125-9157.
- Dominiak, A., Chelstowska, B., Olejarz, W., & Nowicka, G. (2020). Communication in the cancer microenvironment as a target for therapeutic interventions. *Cancers*, 12(5), 1232.
- Ghanbari, B. (2020). On the modeling of the interaction between tumor growth and the immune system using some new fractional and fractional-fractal operators. *Advances in difference Equations*, 2020(1), 585.
- Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016). Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. *Chemical Reviews*, 116(4), 2602-2663.
- Kashyap, K., Handa, M., & Shukla, R. (2020). Azacitidine loaded PLGA nanoparticles and their dual release mechanism.

Current Nanomedicine (Formerly: Recent Patents on Nanomedicine), 10(3), 280-289.

- Kowalczewski, C. J., & Saul, J. M. (2018). Biomaterials for the delivery of growth factors and other therapeutic agents in tissue engineering approaches to bone regeneration. *Frontiers in pharmacology*, 9, 513.
- Kundu, S., Ghosh, M., & Sarkar, N. (2021). State of the art and perspectives on the biofunctionalization of fluorescent metal nanoclusters and carbon quantum dots for targeted imaging and drug delivery. *Langmuir*, 37(31), 9281-9301.
- Lee, S., Lee, S. H., Paulson, B., Lee, J.-C., & Kim, J. K. (2018). Enhancement of local surface plasmon resonance (LSPR) effect by biocompatible metal clustering based on ZnO nanorods in Raman measurements. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 204, 203-208.
- Marhelava, K., Pilch, Z., Bajor, M., Graczyk-Jarzynka, A., & Zagozdzon, R. (2019). Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. *Cancers*, 11(11), 1756.
- Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024). Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. *Pharmaceutics*, 16(3), 332.
- Moradi Kashkooli, F., Soltani, M., Momeni, M. M., & Rahmim, A. (2021). Enhanced drug delivery to solid tumors via drug-loaded nanocarriers: An image-based computational framework. *Frontiers in Oncology*, 11, 655781.
- Özköse, F., Şenel, M. T., & Habbireeh, R. (2021). Fractional-order mathematical modelling of cancer cells-cancer stem cells-immune system interaction with chemotherapy. *Mathematical Modelling and Numerical Simulation with Applications*, 1(2), 67-83.
- Padder, A., Almutairi, L., Qureshi, S., Soomro, A., Afroz, A., Hincal, E., & Tassaddiq, A. (2023). Dynamical analysis of generalized tumor model with Caputo fractional-order derivative. *Fractal and Fractional*, 7(3), 258.
- Raza, F., Zafar, H., Khan, M. W., Ullah, A., Khan, A. U., Baseer, A., Fareed, R., & Sohail, M. (2022). Recent advances in the targeted delivery of paclitaxel nanomedicine for cancer therapy. *Materials Advances*, 3(5), 2268-2290.
- Roy, M., & Finley, S. D. (2019). Metabolic reprogramming dynamics in tumor spheroids: Insights from a multicellular, multiscale model. *PLoS computational biology*, 15(6), e1007053.
- Şen, Ö., Emanet, M., & Ciofani, G. (2021). Nanotechnology-based strategies to evaluate and counteract cancer metastasis and neoangiogenesis. *Advanced healthcare materials*, 10(10), 2002163.
- Vaghi, C., Rodallec, A., Fanciullino, R., Ciccolini, J., Mochel, J. P., Matri, M., Pognard, C., Ebos, J. M., & Benzekry, S. (2020). Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. *PLoS computational biology*, 16(2), e1007178.
- Vieira, L. C., Costa, R. S., & Valério, D. (2023). An overview of mathematical modelling in cancer research: fractional calculus as modelling tool. *Fractal and Fractional*, 7(8), 595.
- Xiang, X., Wang, J., Lu, D., & Xu, X. (2021). Targeting tumor-associated macrophages to synergize tumor immunotherapy. *Signal transduction and targeted therapy*, 6(1), 75.
- Zhan, W., Gedroyc, W., & Xu, X. Y. (2019). Towards a multiphysics modelling framework for thermosensitive liposomal drug delivery to solid tumour combined with focused ultrasound hyperthermia. *Biophysics Reports*, 5(1), 43-59.
- Zhao, R., Ning, X., Wang, M., Yu, A., & Wang, Y. (2021). A multifunctional nano-delivery system enhances the chemo-co-phototherapy of tumor multidrug resistance via mitochondrial-targeting and inhibiting P-glycoprotein-mediated efflux. *Journal of Materials Chemistry B*, 9(44), 9174-9182.
- Zheng, Q. C., Jiang, S., Wu, Y. Z., Shang, D., Zhang, Y., Hu, S. B., Cheng, X., Zhang, C., Sun, P., & Gao, Y. (2020). Dual-targeting nanoparticle-mediated gene therapy strategy for hepatocellular carcinoma by delivering small interfering RNA. *Frontiers in Bioengineering and biotechnology*, 8, 512.
- Zheng, S., Wang, J., Ding, N., Chen, W., Chen, H., Xue, M., Chen, F., Ni, J., Wang, Z., & Lin, Z. (2021). Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. *Journal of Nanobiotechnology*, 19(1), 381.